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INNOVATION HIGHLIGHT

Total Body Photography and Sequential Digital
Dermoscopy Imaging for Melanoma Surveillance in Patients
Starting Natalizumab for Multiple Sclerosis
Tyler Nussinow, BA,¹ Amanda Robinson, NP,¹ Biljana Beretich, MD,² Kathryn Stevens, NP,¹ Elizabeth
Seiverling, MD¹
¹Maine Medical Partners Dermatology, Maine Medical Center, Portland ME, ²Maine Medical Partners Neurology, Maine
Medical Center, Portland ME

Introduction:

Natalizumab is an integrin receptor antagonist that has been approved by the Food and Drug
Administration to treat multiple sclerosis and Crohn’s disease. The drug has been linked to an increased
risk of melanoma. This brief report highlights an innovative clinical approach for monitoring the skin of
patients prescribed natalizumab.

Methods:

We include 2 cases from our skin oncology clinic and a literature review on the incidence of melanoma
in patients prescribed natalizumab between 2004 and 2019.

Results:

In addition to our 2 cases, we found 193 reports of patients with melanoma who were prescribed
natalizumab. We propose an innovative and proactive approach using total body photography and
sequential digital dermoscopy imaging before starting and while treating patients with natalizumab.

Discussion:

Given the mechanism of action of natalizumab, many of the melanomas diagnosed likely arose from
preexisting melanocytic nevi. Using total body photography before starting this high-risk medication and
then sequential digital dermoscopy imaging will increase a dermatologist’s ability to recognize new and
preexisting skin lesions that have evolved since the patient began taking natalizumab.

Conclusions:

Using the latest non-invasive technology to detect skin cancer supports systematic and objective
monitoring of changing melanocytic growths in patients prescribed natalizumab, resulting in earlier
detection of melanoma and greater cure rates.
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N

atalizumab (Tysabri) is a recombinant,
humanized monoclonal antibody that binds
to α4β1-integrin and blocks its interaction
with vascular cell adhesion molecule-1. As a result,
leukocyte migration into brain tissue is inhibited,
reducing inflammation and preventing the formation
of lesions.1 Natalizumab is approved by the Food
and Drug Administration (FDA) to treat multiple
sclerosis (MS) and Crohn’s disease. Typically,
this drug is given via a 1-hour infusion every 4
weeks.2 On average, patients receive natalizumab
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treatments over 30 infusions, or approximately 2.5
years.3
Natalizumab comes with a black box warning
highlighting the increased risk of progressive
multifocal leukoencephalopathy, a viral infection
of the brain that can lead to death.2 Yet, the FDA
prescribing information does not mention that
numerous reports correlated natalizumab and the
development of melanoma, a potentially deadly skin
cancer if not caught early.4,5,6 In one study from Italy,
patients receiving natalizumab for MS were 3 times
more likely to develop melanoma than the general
population.7 It is still unclear how natalizumab
promotes melanoma development. A recent study
by Carbone et al did not find a direct link between
1
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natalizumab treatment and the development of
cutaneous melanoma.8 Rather, natalizumab may
indirectly favor melanoma progression by impairing
the function of natural killer cells, therefore
modifying the tumor microenvironment toward
immune suppression and proangiogenesis.3

approximately 1250 patients with MS and 280
patients with other demyelinating diseases. In
2020, approximately 76 patients at the clinic were
treated with natalizumab.

This brief report highlights an innovative clinical
approach for monitoring the skin in patients
prescribed natalizumab.

Case reports

METHODS
Maine Medical Partners Dermatology has a
dedicated skin oncology clinic with cutting-edge
technology (not widely available) to support their
care of patients prescribed high-risk medications or
who have a history of melanoma or multiple nonmelanoma skin cancers. One type of this technology
is total body photography (TBP). High-quality,
whole-body images of the patient’s pigmented skin
lesions are taken via FotoFinder, a computerized
system that maps moles. This technology also
allows for high-resolution digital dermoscopy with
up to 140× magnification.9 Dermoscopy supports
in vivo evaluation of colors and structures of the
epidermis and parts of the dermis not visible to
the naked eye.10 Sequential digital dermoscopy
imaging (SDDI) offers a time-lapse comparative of
pigmented skin lesions at different time intervals,
supporting detection of changes as subtle as 1/10
millimeter.11 Another type of cutting-edge technology
is reflectance confocal microscopy (RCM). This noninvasive technique supports analysis of growths at
the cellular level in vivo. RCM and TBP have been
shown to aid in melanoma detection.
We include 2 case reports from our skin oncology
clinic. Formal written consent was obtained. We
also reviewed the literature for the incidence of
melanoma in patients prescribed natalizumab.
Information on natalizumab-associated melanomas
was identified by examining peer-reviewed literature
in PubMed from 2004 to 2019 using the keywords
“natalizumab” and “melanoma.” Articles reviewed
were limited to the English language.
Based on our findings of numerous reports
describing natalizumab-associated melanomas,
we partnered with the Center for Comprehensive
MS Care at Maine Medical Partners Neurology
to develop an innovative management strategy
for monitoring skin cancer. This center cares for
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RESULTS
Case 1: A 35-year-old female with no prior history
of skin cancer was given natalizumab for MS for
approximately 3 years before she presented with an
enlarging pigmented growth on the lateral aspect of
her right thigh (Figure 1A). The growth had been
present since her childhood and became darker
and larger shortly after she started treatment with
natalizumab. Dermoscopy revealed a disorganized
pattern within a melanocytic growth. Also present
were shiny white structures, a blue-gray veil,
and dotted vessels (Figure 1B). Due to concern
for melanoma, she underwent a saucerization
skin biopsy for depth and breadth under local
anesthesia. The pathology report showed a
superficial spreading malignant melanoma, stage
1b (0.8 mm, no ulceration), with peripheral and
deep margins free of involvement. Her treatment
with natalizumab was stopped and, per current
guideline recommendations, she was referred to
surgical oncology for a wide local excision and
sentinel lymph node biopsy.12 Negative margins
were achieved and the results of the sentinel lymph
node biopsy were negative. She is currently taking
dimethyl fumarate (Tecfidera) for MS. To date, since
stopping natalizumab, the patient has not presented
with new skin lesions concerning for melanoma.
Case 2: A 37-year-old female with no prior history
of skin cancer was given natalizumab for MS for
6 months before she developed several new
melanocytic growths on her torso and bilateral lower
extremities. Natalizumab was discontinued after 6
doses of therapy. Four months later, a melanoma
was diagnosed on her back. Similar to Case 1, her
treatment for MS was initially switched to Tecfidera.
The patient has since undergone several changes
in therapy and her disease continues to progress.
To date, the patient has had no reports of new or
changing nevi concerning for skin cancer.
Literature review (Table 1)
In addition to 2 cases from our skin oncology clinic,
we found 193 reports of melanoma associated with
natalizumab.4,5,6
2
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A

B

Figure 1. Melanocytic Growth in Patient Prescribed Natalizumab. (A) Clinical photo and (B) polarized
dermoscopic image of 1.6 cm melanocytic growth on lateral aspect of right thigh
Sabol et al detailed an individual case report and
included findings from both the FDA’s Adverse
Event Reporting System and their own literature
search. The impetus behind their investigation
stemmed from the development of a deadly urethral
melanoma in a 43-year-old female with MS taking
natalizumab for more than 2 years. Before April 1,
2014, there were 137 cases of natalizumabassociated melanomas reported to the Adverse
Event Reporting System. An additional 45 cases
were reported between April 1, 2014 and June 30,
2016. Of the cases reported up to April 2014, most
were females being treated with natalizumab for
MS. The median age at melanoma diagnosis was
45. Diagnosis was typically made within 2 years of
natalizumab treatment. Most cases of natalizumabassociated melanoma were treated successfully
with surgery. Nine patients (6.6%) died from
melanoma complications.
In the literature, Sabol et al found 7 additional cases
of patients with MS who were taking natalizumab
and developed melanoma, confirmed by biopsy. All
but 1 case involved a female. The median age was
41 years, and the melanoma diagnosis occurred
after a median of 12 doses of natalizumab. These 7
published cases include those reported by Vavricka
et al and Mullen et al, which were part of our
literature review.
Vavricka et al reported 1 case of a 41-year-old
female with a history of atypical nevi who was taking
natalizumab for MS for approximately 15 months.
At this time, she developed a rapidly growing nevus
on her upper arm that was later diagnosed as
melanoma in situ and was excised successfully.
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Mullen et al wrote a letter to the editor of the New
England Journal of Medicine highlighting 2 cases
of natalizumab-associated melanoma in women in
their mid-forties with a diagnosis of MS. One patient
was a 46-year-old female who noticed a rapidly
changing nevus on her shoulder shortly after taking
her first dose of natalizumab. The biopsy revealed a
thick, non-ulcerated melanoma with metastases to
the lymph nodes. The second patient was a 45-yearold female who developed ocular melanoma from
a longstanding ocular nevus after taking several
doses of natalizumab.
Innovative proposal
We propose an innovative and proactive approach
using TBP and SDDI before starting and while
treating patients with natalizumab.
1. Before starting natalizumab, the patient should
be seen by a dermatologist for a full-body skin
examination with dermoscopy.
a. Lesions that are worrisome for melanoma
should be either biopsied or further evaluated
using RCM.
2. The patient should undergo baseline TBP with
digital dermoscopic imaging.
3. The patient should be evaluated against
baseline images every 4 to 6 months. New or
changing growths should be biopsied.
We suspect our patients (and many of the reported
cases) had tenuous melanocytic growths before
starting natalizumab treatment, and the medication
enabled the progression by adversely impacting

3
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Table 1. Literature Review of Case Reports of Natalizumab-Associated Melanomas
Author

Sabol et al
(2017)

Age, y

43

F

38

M

Sabol et
al (2017),
Mullen et al
(2008)

Clinical features

Unknown
Polyp in distal urethra
(estimated 2.2 y of
positive for melanoma.
treatment)

Other information
Patient died from
widely metastatic
malignant urethral
melanoma.

5

--

Patient died from
melanoma.

Therapy stopped after
16 doses.

39

F

5

After 10 months, ulcerated
and ablated. 1.6 mm
thickness and Clark level
IV. No metastasis to lymph
nodes.

38

F

77

Malignant melanoma. Clark
level III and Breslow index
0.5 mm.

No evidence of
metastasis.

35

5 months after last dose,
noticed enlarging mole on
right shin. Lesion was flat
with a dark center.

No evidence of
metastasis or
recurrence.

12

Superficial spreading
melanoma from a dysplastic
nevus on upper arm.

Had many atypical
moles for years.
Melanoma occurrence
close to therapy start.

1

Mole on shoulder for a long
time before melanoma.
Had metastatic spread to
regional lymph nodes.

After discontinuing
therapy, patient
developed widely
metastatic melanoma.

Several

Ocular melanoma. Long
history of mole in posterior
eye. Mole was unchanged
for 6 years before therapy.

Family history of
melanoma.

48

Sabol et
al (2017),
Vavricka et
al (2011)

Sex

# of doses at
melanoma
diagnosis

41

46

45

F

F

F

F

DISCUSSION
The majority of melanomas diagnosed in patients
taking natalizumab develop within approximately 2
years of beginning therapy, as was shown with Case
2.4 When melanoma is caught early, cure rates are
nearly 100%.13 For patients prescribed natalizumab,
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current recommendations include a full-body skin
examination conducted by a dermatologist every 6
months after starting treatment.4 However, given the
mechanism of action of natalizumab, many of the
melanomas diagnosed likely arose from preexisting
melanocytic nevi, as seen in Case 1.
4
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immune surveillance. Thus, instead of waiting
until a patient has already started treatment with
natalizumab, we propose an innovative and
proactive approach using TBP and SDDI. Much
literature supports our assertion that TBP and SDDI
will increase a dermatologist’s ability to recognize
new and preexisting skin lesions that have evolved
since a patient began taking natalizumab.14,15,16,17 In
patients over age 50, 30% of new growths identified
with TBP are melanoma.6 Furthermore, using TBP
and SDDI, one study monitored 11,396 lesions on
629 patients at high risk for developing melanoma.14
A total of 98 melanomas (8.5% of excised lesions)
were diagnosed in 78 patients (12.6%). These
lesions were identified at an early stage; 53 were
superficial (in situ), 45 had a Breslow index (depth of
tumor invasion) of < 1.0 mm (median 0.5 mm), and
all were without ulceration (presence of ulceration
portends a higher risk for metastasis).14

CONCLUSIONS
Patients prescribed natalizumab have an increased
risk for developing melanoma from new and
preexisting skin lesions. Proactive TBP and SDDI
using our innovative approach supports improved
monitoring of melanocytic skin growths in a
systematic, objective way that may detect melanoma
at earlier stages in high-risk patients. For optimal
outcomes, a partnership is essential between the
neurologist who prescribes natalizumab and the
dermatologist who monitors the skin.
Lastly, this brief report is timely. In October 2020, the
Journal of the American Academy of Dermatology
issued a statement encouraging dermatologists to
use TBP with SDDI and RCM to aid in detecting
skin melanoma.18 The skin oncology clinic at Maine
Medical Partners offers all these cutting-edge
technologies.
Conflict of Interest: None
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